Relationship of serum irisin levels to prevalence and progression of coronary artery calcification: A prospective, population-based study

• Published in: International journal of cardiology 2018-09, Vol.267, p.177-182
• Main Authors: Hisamatsu, Takashi, Miura, Katsuyuki, Arima, Hisatomi, Fujiyoshi, Akira, Kadota, Aya, Kadowaki, Sayaka, Zaid, Maryam, Miyagawa, Naoko, Satoh, Atsushi, Kunimura, Ayako, Horie, Minoru, Ueshima, Hirotsugu
• Format: Article
• Language: English
• Subjects: Adult; Aged; Biomarkers; Biomarkers - blood; Coronary artery calcification; Coronary Artery Disease - diagnosis; Coronary Artery Disease - metabolism; Coronary Vessels - diagnostic imaging; Coronary Vessels - metabolism; Correlation of Data; Disease Progression; Epidemiology; Exercise; Fibronectins - blood; Humans; Japan; Male; Middle Aged; Prevalence; Prospective cohort study; Prospective Studies; Risk Factors; Tomography, X-Ray Computed; Vascular Calcification - diagnostic imaging; Vascular Calcification - metabolism
• ISSN: 0167-5273; 1874-1754
• DOI: 10.1016/j.ijcard.2018.05.075

The mechanisms by which exercise reduces the risk of coronary heart disease remain poorly understood. Irisin, an exercise-induced polypeptide secreted from skeletal muscles, is proposed to potentially mediate beneficial effects of exercise, especially in metabolic regulation and development of atherosclerosis. We examined whether higher serum irisin levels are associated with lower prevalence and progression of coronary atherosclerosis. We performed a prospective, population-based study of Japanese men aged 40–79 years without known coronary heart disease. We measured baseline serum irisin levels using an enzyme-linked immunosorbent assay and quantified coronary artery calcification (CAC) from serial computed tomography scans. Of 1038 participants (mean age, 63.9 years) at baseline, 670 (64.6%) had prevalent CAC. Of 810 participants at follow-up (median, 5.1 years), 407 (50.3%) experienced CAC progression. In Poisson regression with robust error variance adjusted for age and behavioral factors, serum irisin levels were inversely associated with CAC prevalence (relative risk [RR] of 4th versus 1st quartiles [95% confidence interval], 0.88 [0.78–0.99]; trend P = 0.016) and CAC progression (RR, 0.76 [0.63–0.91]; trend P = 0.002). After further adjustment for cardiometabolic risk factors, the inverse association with CAC prevalence disappeared (RR, 0.95 [0.84–1.08]; trend P = 0.319), but that with CAC progression persisted (RR, 0.77 [0.64–0.93]; trend P = 0.003). These associations were consistent when we applied ordinal logistic regression and across subgroups by cardiometabolic risk factor status. Higher serum irisin levels were associated with less burden of coronary atherosclerosis. This association would be mediated through and beyond traditional cardiometabolic pathways. •Higher serum irisin levels were related to a lower coronary atherosclerotic burden.•This relation may be mediated via and beyond traditional cardiometabolic pathways.•Irisin could be a predictive marker or therapeutic strategy against CHD.